Recombinant PDCD1 (Balstilimab Biosimilar) antibody
The Mammalian Cells Monoclonal anti-PDCD1 (Balstilimab Biosimilar) antibody is suitable to detect PDCD1 (Balstilimab Biosimilar) in samples from Human. It has been validated for ELISA.
Catalog No. ABIN7488211
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant PDCD1 (Balstilimab Biosimilar) antibody (ABIN7488211)
Target
PDCD1 (Balstilimab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This PDCD1 (Balstilimab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Balstilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb
-
Characteristics
- Antibody Type: IgG4-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG4 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- PDCD1 (Balstilimab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
AGEN2034
PD-1 monoclonal antibody balstilimab is used to treat cervical cancer, balstilimab monotherapy and anti-CTLA-4 monoclonal antibody zalifrelimab combined with balstilimab for metastatic cervical cancer. -
CAS-No
- 2230167-06-1
Target
-
You are here:
